Developmental

$275,462P30FY2013CANIH

Research Inst Of Fox Chase Can Ctr, Philadelphia PA

Investigators

Linked publications, trials & patents

Paper 39604567 Paper 39602533 Paper 39554190 Paper 39546469 Paper 39521739 Paper 39514554 Paper 39371220 Paper 39345610 Paper 39343653 Paper 39223207 Paper 39207123 Paper 39189642 Paper 39148468 Paper 39137728 Paper 39072643 Paper 39060143 Paper 39013784 Paper 39003201 Paper 38982062 Paper 38976159 Paper 38963567 Paper 38914477 Paper 38871720 Paper 38865671 Paper 38853421 Paper 38835516 Paper 38815457 Paper 38811332 Paper 38798370 Paper 38766032 Paper 38747616 Paper 38678525 Paper 38659828 Paper 38639476 Paper 38638131 Paper 38600381 Paper 38586274 Paper 38586042 Paper 38559274 Paper 38547779 Paper 38539515 Paper 38464238 Paper 38452871 Paper 38432028 Paper 38421650 Paper 38377387 Trial NCT04290585 Trial NCT03177057 Trial NCT02594826 Trial NCT02132884 Trial NCT02132858 Trial NCT02132845 Trial NCT02110953 Trial NCT02092714 Trial NCT02050009 Trial NCT01982591 Trial NCT01962948 Trial NCT01934179 Trial NCT01840150 Trial NCT01462630 Trial NCT01316757 Trial NCT01212822 Trial NCT00750009 Trial NCT00509626 Trial NCT00458588 Trial NCT00436397 Trial NCT00433524 Trial NCT00084591 Trial NCT00084539 Trial NCT00084526 Trial NCT00084513 Trial NCT00066677 Trial NCT00062322 Trial NCT00062309 Trial NCT00043108 Trial NCT00039520 Trial NCT00039507 Trial NCT00022308 Trial NCT00021398 Trial NCT00021372 Trial NCT00021346 Trial NCT00021333 Trial NCT00021320 Trial NCT00005037 Trial NCT00003264 Trial NCT00003263 Trial NCT00003109 Patent 9533040 Patent 9182383 Patent 9101603 Patent 8980258 Patent 8685658 Patent 8609437 Patent 8580263 Patent 8329873 Patent 7332585 Patent 7332580 Patent 7129057 Patent 6946275 Patent 6617427

Abstract

PROJECT SUMMARY (See instructions): Developmental funds are requested to recruit faculty level scientists in areas of strategic need, to support pilot projects that allow Fox Chase Cancer Center scientists to pursue innovative ideas in high priority research areas, and to support technology and methodology development projects related to the Center's discovery mission and strategic objectives. In the past CCSG cycle, 40 investigators were recruited and, with the exclusion of our 17 newest recruits, 19 of 23 (83%) have obtained $15.4 million in peer reviewed funding within 24 months of their appointment Of that amount $5.1 million was garnered by investigators directly leveraging developmental funds. Also, this class competed successfully for a further $1.6 million in competitive foundation support. During the last CCSG cycle, pilot project funds were utilized in the second, fifth and sixth years to support potential high-impact projects, largely from established investigators. The 12 funded projects have already produced two funded grants and seven publications. During the past CCSG cycle, the Center provided start up support for a High Throughput Screening Facility that has become one of the 16 established shared facilities. In the present CCSG application we seek partial support for the 25 new investigators identified as necessary to address the critical mass needs of the Center's five existing programs over the next CCSG cycle. This request represents less than 25% of the average cost of supporting a new investigator. We also seek support for partial funding for four translational pilot projects per year. These CCSG funds will be matched by institutional funds. Finally, we seek partial funding for technology developments and informatics initiatives in support of the Center's Institute for Personalized Medicine. All of these developmental funds are considered vital to achieving the discovery objectives outlined in the Center's Strategic Plan.

View original record on NIH RePORTER →